Cargando…

Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients

INTRODUCTION: Dalcinonacog alfa (DalcA), a novel subcutaneously administered recombinant human factor IX (FIX) variant is being developed for adult and paediatric patients with hemophilia B (HB). DalcA has been shown to raise FIX to clinically meaningful levels in adults with HB. This work aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faraj, Alan, Le Moan, Natacha, Gorina, Eduard, Blouse, Grant E., Knudsen, Tom, Simonsson, Ulrika S. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427527/ https://www.ncbi.nlm.nih.gov/pubmed/37341915 http://dx.doi.org/10.1007/s12325-023-02570-6

Ejemplares similares

Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
por: Faraj, Alan, et al.
Publicado: (2022)

Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
por: Faraj, Alan, et al.
Publicado: (2023)

Activity measurements of dalcinonacog alfa
por: Williams, Stella C., et al.
Publicado: (2020)

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa
por: Nichols, Timothy C., et al.
Publicado: (2020)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2016)

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
por: Lissitchkov, Toshko, et al.
Publicado: (2023)

Aspects of prophylactic treatment of hemophilia
por: Ljung, Rolf
Publicado: (2016)

Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
por: Lissitchkov, Toshko, et al.
Publicado: (2022)

Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF‐CC) in Subjects With Severe Hemophilia A
por: Korth‐Bradley, Joan, et al.
Publicado: (2018)

Profile of efraloctocog alfa and its potential in the treatment of hemophilia A
por: George, Lindsey A, et al.
Publicado: (2015)

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A
por: Napolitano, Mariasanta, et al.
Publicado: (2019)

Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B
por: Djambas Khayat, Claudia
Publicado: (2016)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
por: Zanon, Ezio
Publicado: (2023)

Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example
por: Keutzer, Lina, et al.
Publicado: (2020)

Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A
por: Takedani, Hideyuki, et al.
Publicado: (2015)

Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A
por: Hyun, Shin Young, et al.
Publicado: (2015)

Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review
por: Sella, Carola, et al.
Publicado: (2023)

Patient and parent preferences for characteristics of prophylactic treatment in hemophilia
por: Furlan, Roberto, et al.
Publicado: (2015)

Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials
por: Witarto, Bendix Samarta, et al.
Publicado: (2022)

Apixaban and eftrenonacog alfa treatment in a patient with moderate hemophilia B and cardiovascular disease
por: Santoro, Rita C., et al.
Publicado: (2021)

Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients
por: Faraj, Alan, et al.
Publicado: (2020)

Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results
por: John, M. Joseph, et al.
Publicado: (2020)

Neurosurgery in a patient with severe hemophilia B: an experience using eftrenonacog alfa as perioperative management
por: Benitez Hidalgo, Olga, et al.
Publicado: (2022)

A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis
por: Clewe, Oskar, et al.
Publicado: (2020)

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
por: Male, Christoph, et al.
Publicado: (2022)

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
por: Goedhart, Tine M.H.J., et al.
Publicado: (2022)

Validation of the Brazilian version of the VERITAS-Pro scale to assess adherence to prophylactic regimens in hemophilia
por: Ferreira, Adriana Aparecida, et al.
Publicado: (2018)

The frequency of complications in a cohort of patients diagnosed with hemophilia A and hemophilia B receiving prophylactic treatment in Colombia: A retrospective noninterventional study
por: Machado Alba, Jorge E., et al.
Publicado: (2023)

Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies
por: Yang, Renchi, et al.
Publicado: (2020)

Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
por: Yang, Renchi, et al.
Publicado: (2022)

Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions
por: Faraj, Alan, et al.
Publicado: (2020)

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa
por: Lentz, S R, et al.
Publicado: (2014)

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
por: Klamroth, Robert, et al.
Publicado: (2021)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Extended dosing of darbepoetin alfa in peritoneal dialysis patients
por: Feriani, Mariano, et al.
Publicado: (2011)

Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE)
por: Young, Guy, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_frnv3am83dfqb7au49o91c592g